Stock Events

Stock Events

XORTX Therapeutics 

€1.3850
42
-€0.02-1.42% Monday 07:16

Statistics

Day High
0.277
Day Low
0.277
52W High
0.89
52W Low
0.249
Volume
-
Avg. Volume
-
Mkt Cap
7.22M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
-0.46
-0.29
-0.12
0.05
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-6.25MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, potentially overlapping with XORTX's focus on kidney diseases and conditions that could have similar treatment approaches.
Aurinia Pharmaceuticals
AUPH
Mkt Cap2.17B
Aurinia Pharmaceuticals focuses on the development of therapies for autoimmune diseases, including lupus nephritis, which could compete with XORTX's kidney-focused therapies.
Akebia Therapeutics
AKBA
Mkt Cap243.47M
Akebia Therapeutics works on treatments for kidney disease and anemia, areas that overlap with XORTX's therapeutic focus, making them direct competitors.
Ardelyx
ARDX
Mkt Cap983.69M
Ardelyx focuses on kidney and cardiovascular diseases, offering treatments that could compete with XORTX's products for similar indications.
Trevena
TRVN
Mkt Cap9,501
Trevena develops therapies for central nervous system disorders but has potential overlap in treatment methodologies that could be applied to conditions XORTX targets.
Outlook Therapeutics
OTLK
Mkt Cap156.5M
Outlook Therapeutics is focused on ocular diseases but represents the broader competition in the biopharmaceutical sector, competing for investment and resources.

About

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Show more...
CEO
ISIN
CA98420Q3061
WKN
000A3EUNZ

Listings

STU
DE
ANU.STU
MU
DE
ANU.MU
STU
DE
ANUA.STU
MU
DE
ANU1.MU

0 Comments

Share your thoughts

FAQ

What is XORTX Therapeutics stock price today?▼
The current price of ANUA.F is €1.39 EUR — it has decreased by -1.42% in the past 24 hours. Watch XORTX Therapeutics stock price performance more closely on the chart.
What is XORTX Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange XORTX Therapeutics stocks are traded under the ticker ANUA.F.
Is XORTX Therapeutics stock price growing?▼
ANUA.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year XORTX Therapeutics has showed a -54.44% decrease.
What is XORTX Therapeutics market cap?▼
Today XORTX Therapeutics has the market capitalization of 7.22M
What is XORTX Therapeutics revenue for the last year?▼
XORTX Therapeutics revenue for the last year amounts to 0 EUR.
What is XORTX Therapeutics net income for the last year?▼
ANUA.F net income for the last year is -6.25M EUR.
In which sector is XORTX Therapeutics located?▼
XORTX Therapeutics operates in the Other sector.
When did XORTX Therapeutics complete a stock split?▼
The last stock split for XORTX Therapeutics was on April 06, 2026 with a ratio of 1:5.